Russell Alan J. - 28 Sep 2021 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Scientific Officer, Director
Signature
/s/ John R. Moore, Attorney-in-Fact for Russell Alan J
Issuer symbol
EWTX
Transactions as of
28 Sep 2021
Net transactions value
-$452,483
Form type
4
Filing time
30 Sep 2021, 19:16:11 UTC
Previous filing
27 Sep 2021
Next filing
05 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Sale $252,753 -14,610 -7.1% $17.30 190,944 28 Sep 2021 Direct F1, F2
transaction EWTX Common Stock Sale $188,934 -11,226 -5.9% $16.83 179,718 29 Sep 2021 Direct F3
transaction EWTX Common Stock Sale $10,796 -618 -0.34% $17.47 179,100 29 Sep 2021 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.985 to $17.93, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.36 to $17.36, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.37 to $17.71, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.